

## Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

### Product

**Name of Product:** Biotechnology Fund, Class I EUR Distribution Shares

**PRIP Manufacturer:** Polar Capital LLP

The product is manufactured by Polar Capital LLP (the "Investment Manager"). The Investment Manager is authorised and regulated in the UK by the Financial Conduct Authority. The product is managed by MJ Hudson Fund Management (Ireland) Limited (the "Manager").

**ISIN:** IE00B3WVRB16

**Website:** [www.polarcapital.co.uk](http://www.polarcapital.co.uk)

Call +44 (0) 20 7227 2700 for more information.

Bridge Fund Management Limited is authorised in Ireland and regulated by the Central Bank of Ireland (CBI).

**This Key Information Document is accurate as at 30 April 2023.**

### What is this product?

#### Type

The Polar Capital Biotechnology Fund (the "Fund") is an investment fund. The Fund is a sub-fund of Polar Capital Funds Plc, an open ended investment company, incorporated with limited liability in Ireland.

#### Term

This product does not have a maturity date.

#### Objectives

The objective of the Fund is to preserve capital and achieve long term capital appreciation by investing worldwide in the shares of biotechnology, diagnostics and life sciences tools companies.

#### Intended Retail Investor

This product is intended for all investors (including those with a basic level of investment knowledge) who are seeking a return on their investment and who can accept the risk of losing some or all of their original investment. The product should be considered a long-term investment, defined as five years or more. This product is suitable for investors seeking an investment with sustainable characteristics.

This is an Undertaking for the Collective Investment in Transferable Securities (UCITS) product.

**Depository** Northern Trust Fiduciary Services (Ireland) Limited, Georges Court, 54-62 Townsend Street, Dublin,

Ireland D02 R156. The share price is listed on the Euronext Dublin, this can be found at [www.euronext.com/en](http://www.euronext.com/en). Further information and corporate documentation including the latest and historic Annual and Interim Reports, can be obtained from the website: [www.polarcapital.co.uk](http://www.polarcapital.co.uk)

#### Investment Policy

The Fund is broadly diversified across countries, biotechnology sectors and by market-cap (a measure of company size). The Fund may invest in financial derivatives (complex instruments based upon the value of underlying assets) for hedging, to reduce risk, to manage the Fund more efficiently, or to gain exposure to securities in a more efficient way. The Fund is actively managed and uses the NASDAQ Biotechnology Net Total Return Index (EUR) benchmark as a performance target and to calculate the performance fee. The currency of the Fund is US Dollar and the currency of this share class is Euro.


Any income which the Fund generates may be paid out in the form of an annual dividend at the sole discretion of the Directors.

#### Sustainable Finance Disclosure Regulation

This Fund promotes environmental and/or social characteristics and is classified as an Article 8 fund under the EU's Sustainable Finance Disclosure Regulation ("SFDR"). For more information please see the Fund's prospectus or by visiting [www.polarcapital.co.uk](http://www.polarcapital.co.uk).

### What are the risks and what could I get in return?

#### Risk Indicator



The risk indicator assumes that you keep the product for 5 years. The actual risk can vary significantly if you cash in at an early stage and you may get back less.

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.

This rates the potential losses from future performance at a medium-high level, and poor market conditions will likely impact the capacity of the PRIIPs manufacturer to pay you.

We have classified this product as 5 out of 7, which is a medium-high risk class.

**If the product currency differs from your investment currency, the following applies: Be aware of currency risk. You will receive payments in a different currency, so the final return you will get depends on the exchange rate between the two currencies. This risk is not considered in the indicator shown above.**

Due to effects of unusual market conditions, other risks could be triggered. Please see below for more detail.

This product does not include any protection from future market performance so you could lose some or all of your investment.

If we are not able to pay you what is owed, you could lose your entire investment.

**Concentration Risk** – the Fund invests in a relatively concentrated number of companies and industries. This focused strategy can produce high gains but can also lead to significant losses. The Fund may be less diversified than other investment funds.

**Investment Risk** – the Fund invests in company shares globally, and share prices can rise or fall due to a number of factors affecting

global stock markets.

**Derivative Risk** – certain derivatives may result in gains or losses that are greater than the original amount invested. Derivatives also involve counterparty risk, which is the risk that a counterparty to the derivative contract cannot meet its contractual obligations.

**Currency Risk** – the Fund invests in assets denominated in currencies other than the Fund's base currency. Changes in exchange rates may have a negative impact on the Fund's investments.

## Performance Scenarios

The figures shown include all the costs of the product itself, but may not include all the costs that you pay to your advisor or distributor. The figures do not take into account your personal tax situation, which may also affect how much you get back.

What you will get from this product depends on future market performance. Market developments in the future are uncertain and cannot be accurately predicted.

The unfavourable, moderate, and favourable scenarios shown are illustrations using the worst, average, and best performance of the product and a suitable benchmark over the last 10 years. Markets could develop very differently in the future.

The stress scenario shows what you might get back in extreme market circumstances.

The unfavourable scenario occurred for an investment between August 2021 and April 2023.

The moderate scenario occurred for an investment between July 2017 and July 2022.

The favourable scenario occurred for an investment in the benchmark between June 2013 and June 2018.

**Recommended holding period: 5 years**

**Example Investment: EUR 10,000.**

		<b>If you exit after 1 year</b>	<b>If you exit after 5 years</b>
Stress	What you might get back after costs	1,270 EUR	1,090 EUR
	Average return each year	-87.33 %	-35.80 %
Unfavourable	What you might get back after costs	7,220 EUR	9,160 EUR
	Average return each year	-27.79 %	-1.74 %
Moderate	What you might get back after costs	11,130 EUR	19,260 EUR
	Average return each year	11.29 %	14.00 %
Favourable	What you might get back after costs	18,270 EUR	30,600 EUR
	Average return each year	82.69 %	25.07 %

## What happens if Polar Capital LLP is unable to pay out?

Losses are not covered by an investor compensation or guarantee scheme.

The depository would liquidate the investments and distribute the proceeds to the investors. In the worst case, however, you could lose your entire investment.

## What are the costs?

**The person advising on or selling you this product may charge you other costs. If so, this person will provide you with information about these costs and how they affect your investment.**

### Costs over time

The tables show the amounts that are taken from your investment to cover different types of costs. These amounts depend on how much you invest, how long you hold the product and how well the product does. The amounts shown here are illustrations based on an example investment amount and different possible investment periods.

We have assumed:

- In the first year, you would get back the amount that you invested (0 % annual return). For the other holding periods we have assumed the product performs as shown in the moderate scenario.

- EUR 10,000 is invested.

	<b>If you exit after 1 year</b>	<b>If you exit after 5 years</b>
Total costs	686 EUR	2,975 EUR
Annual cost impact (*)	6.9%	3.3% each year

(\*) This illustrates how costs reduce your return each year over the holding period. For example it shows that if you exit at the recommended holding period your average return per year is projected to be 17.3% before costs and 14.0% after costs.

Figures may not sum due to rounding

## Composition of costs

<b>One-off costs upon entry or exit</b>		<b>If you exit after 1 year</b>
Entry costs	The product reserves the right to charge an entry fee of up to 5% of the subscription price. As of the date of this document, we do not charge an entry fee.	Up to 500 EUR
Exit costs	We do not charge an exit fee for this product.	0 EUR
<b>Ongoing costs [taken each year]</b>		
Management fees and other administrative or operating costs	The costs that we take each year for managing your investment.	112 EUR
Transaction costs	The impact of the costs of us buying and selling underlying investments for the product.	5 EUR
<b>Incidental costs taken under specific conditions</b>		
Performance fees	The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years.	70 EUR

## How long should I hold it and can I take money out early?

### Recommended holding period: 5 years

Please refer to the Fund's Prospectus for information on redeeming your investment.

## How can I complain?

If you have a complaint about the product, this document or the conduct of the manufacturer, please contact Polar Capital's investor relations team via email: [Investor-Relations@polarcapital.co.uk](mailto:Investor-Relations@polarcapital.co.uk). Alternatively, you can also write to Polar Capital, 16 Palace Street, London SW1E 5JD, United Kingdom.

## Other relevant information

Share prices will be published on [www.polarcapital.co.uk](http://www.polarcapital.co.uk) on each valuation day. Please refer to the Fund's prospectus for information on buying and selling shares in the Fund. Shares can be bought and sold on days where banks are normally open for business in the United Kingdom and the domiciliary country of the Fund.

The information contained in this document is supplemented by the Fund's Prospectus, relevant Fund Supplement, the Articles of Incorporation and the annual and semi-annual financial statements which are available to download free of charge from [www.polarcapital.co.uk](http://www.polarcapital.co.uk). A paper copy of the KID is available upon request and free of charge by contacting [Investor-Relations@polarcapital.co.uk](mailto:Investor-Relations@polarcapital.co.uk).

The Fund is a sub-fund of Polar Capital Funds Plc, domiciled in Ireland. The Fund is managed by Bridge Fund Management Limited. The Fund's investment manager is Polar Capital LLP. The administrative services are provided by Northern Trust International Fund Administration Services (Ireland) Limited and the depositary services are provided by Northern Trust Fiduciary Services (Ireland) Limited. The Fund is subject to tax laws and regulations of the domiciliary country. Depending on your home country of residence, this might have an impact on your investment. Please speak to your financial adviser for further information.

The paying and representative agent in Switzerland is BNP Paribas Securities Services, Paris, succursale de Zurich, Selnaustrasse 16, 8002 Zürich, Switzerland. The Prospectus, the Key Information Documents (KIDs), the Articles of Association and the annual and semi-annual reports can be obtained free of charge from the representative agent in Switzerland.